Cost of Compounded GLP-1 vs. Brand-Name Wegovy, Ozempic, Zepbound, and Mounjaro

What Does Compounded GLP-1 Actually Cost in 2025?

Compounded semaglutide runs $199 to $399 per month through most licensed telehealth platforms in 2025, and compounded tirzepatide runs $249 to $499 per month. These prices reflect 503A compounding pharmacies dispensing patient-specific preparations and 503B outsourcing facilities producing larger batches. The precise cost depends on dose, the pharmacy's overhead, and whether a telehealth consultation fee is bundled in.

Pricing at this level is possible because compounding pharmacies source active pharmaceutical ingredients (APIs) directly, bypassing the brand manufacturer's supply chain and the associated marketing costs. A 2.4 mg weekly semaglutide dose in a compounded vial costs the pharmacy far less than a Wegovy auto-injector pen costs Novo Nordisk to manufacture and distribute through its retail channel.

Several factors push the actual out-of-pocket price up or down. Starting doses are lower (0.25 mg semaglutide or 2.5 mg tirzepatide) and therefore cheaper per injection, while maintenance doses at the top of the titration schedule cost more per vial. Some platforms charge a flat monthly subscription that includes physician oversight, shipping, and medication; others bill separately for each component. When comparing quotes across providers, confirm whether the listed price covers the full maintenance dose or only the lowest starting dose.

Compounded GLP-1 preparations are not FDA-approved products. The FDA has removed semaglutide from its drug shortage list as of early 2025, which places new regulatory pressure on compounders. 503B outsourcing facilities may continue to compound certain tirzepatide preparations under specific conditions. Patients considering compounded products should confirm their pharmacy holds a valid state license and a current 503A or 503B designation.

Brand-Name Wegovy Cost Without Insurance

Wegovy (semaglutide 2.4 mg) has a 2025 list price of approximately $1,349 per month for the maintenance dose. That figure represents the wholesale acquisition cost before pharmacy markups, coupons, or manufacturer assistance programs are applied.

Novo Nordisk's NovoCare program offers Wegovy for $0 per month to commercially insured patients who meet income criteria and for $650 per month to uninsured patients. Patients earning under 400% of the federal poverty level may qualify for free medication through the patient assistance program. Without any assistance and without insurance, a 68-week course of Wegovy at the dose used in STEP-1 would cost roughly $22 to 900 in medication alone.

STEP-1 (N=1,961) showed that semaglutide 2.4 mg produced a mean 14.9% reduction in body weight at 68 weeks versus 2.4% for placebo (P<0.001) [1]. The same trial reported that 86.4% of semaglutide participants lost at least 5% of body weight, compared with 31.5% in the placebo group. These are the efficacy numbers that justify Wegovy's FDA approval for chronic weight management in adults with BMI <30 kg/m² and at least one weight-related comorbidity, or BMI <27 kg/m² [2].

The SELECT cardiovascular outcomes trial (N=17,604) showed a 20% relative risk reduction in major adverse cardiovascular events with semaglutide 2.4 mg over 33.5 months versus placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes [3]. That cardiovascular data strengthened insurer and payer interest in covering Wegovy, though coverage decisions lag the clinical evidence considerably.

Brand-Name Ozempic Cost Without Insurance

Ozempic (semaglutide, approved doses 0.5 mg, 1 mg, and 2 mg) lists at approximately $968 per month in 2025. Ozempic carries FDA approval for type 2 diabetes (T2D) management, not for weight loss specifically. Many patients with T2D receive Ozempic under commercial insurance with relatively low copays because the diabetes indication is broadly covered.

Patients without T2D who are prescribed Ozempic off-label for weight management cannot rely on most insurance plans to cover it. Off-label prescriptions exist in a coverage gray zone: some plans pay, most do not. The Savings Card program from Novo Nordisk has historically reduced out-of-pocket costs to as little as $25 per month for eligible commercially insured patients, but eligibility criteria change year to year.

STEP-2 (N=1,210), conducted in adults with T2D and overweight or obesity, reported that semaglutide 2.4 mg achieved 9.6% body weight reduction versus 3.4% with placebo at 68 weeks [4]. For T2D patients, glycated hemoglobin (HbA1c) reductions also reached 1.6 percentage points more than placebo.

Brand-Name Zepbound Cost Without Insurance

Zepbound (tirzepatide for chronic weight management) carries a 2025 list price near $1,060 per month for the 10 mg or 15 mg maintenance doses. Eli Lilly's LillyDirect program sells Zepbound as single-dose vials directly to self-pay patients for $349 per month (2.5 mg or 5 mg) to $499 per month (10 mg or 15 mg), which is a meaningful reduction from the retail list price and a program worth knowing about if insurance does not cover the drug.

SURMOUNT-1 (N=2,539) established tirzepatide's weight loss efficacy: at 72 weeks, the 15 mg dose produced a mean 22.5% reduction in body weight versus 2.4% for placebo (P<0.001) [5]. Tirzepatide works on both GIP and GLP-1 receptors, and the dual agonism appears to produce greater weight loss than GLP-1 receptor agonism alone, based on the head-to-head comparison implied by cross-trial data. SURMOUNT-4 (N=670) demonstrated that patients who discontinued tirzepatide regained a mean 14% of body weight over 52 weeks after stopping, while those who continued lost a further 5.5% [6].

The Zepbound FDA label confirms approval for adults with initial BMI <30 kg/m², or BMI <27 kg/m² with at least one weight-related condition including hypertension, dyslipidemia, T2D, obstructive sleep apnea, or cardiovascular disease [7].

Brand-Name Mounjaro Cost Without Insurance

Mounjaro (tirzepatide for T2D) lists at approximately $1,023 per month. Like Ozempic and Wegovy, the difference between Mounjaro and Zepbound is the FDA indication, not the active ingredient. Mounjaro is approved for T2D; Zepbound is approved for obesity. Eli Lilly offers a Mounjaro Savings Card that reduces the cost to $25 per month for eligible commercially insured patients.

SURMOUNT-2 (N=938), conducted in adults with T2D and overweight or obesity, found that tirzepatide 15 mg produced a 15.7% reduction in body weight at 72 weeks versus 3.3% for placebo [8]. HbA1c fell by 2.58 percentage points with the 15 mg dose. These are the numbers a clinician and insurer weigh when deciding whether Mounjaro is appropriate for a patient with T2D.

Insurance coverage for Mounjaro through the T2D indication is substantially better than coverage for Zepbound through the obesity indication. A patient with documented T2D may pay $25 or less monthly with commercial insurance and the savings card, while the same patient without a T2D diagnosis seeking the drug for weight management faces list price or a high prior-authorization burden.

Insurance Coverage: What Actually Gets Paid

Commercial insurance covers Ozempic for T2D in most plans. Wegovy coverage varies widely: a 2024 KFF analysis found that fewer than half of large employer plans covered anti-obesity medications consistently. Medicare Part D is prohibited by statute from covering drugs prescribed primarily for weight loss, meaning Wegovy and Zepbound are generally excluded unless a legislative change occurs. Ozempic and Mounjaro may be covered under Part D for their diabetes indications.

Medicaid coverage depends on state. About 14 states explicitly cover anti-obesity medications as of 2025, while the majority do not. The AACE/ACE obesity clinical practice guidelines state that "pharmacotherapy for obesity should be considered when lifestyle intervention alone does not achieve the desired weight loss goal," and they list GLP-1 receptor agonists as first-line agents [9]. Despite this guideline support, payer coverage has not kept pace.

Prior authorization is common for all four brand-name drugs. Requirements typically include a BMI threshold, documentation of a failed lifestyle intervention, and sometimes a specific comorbidity. Expect one to four weeks for prior authorization to resolve, and expect an appeals process if the initial request is denied.

Compounded vs. Brand: The Real Trade-Off

The price gap between compounded and brand is real. At $299 per month for compounded semaglutide versus $1,349 for Wegovy, the annual savings exceed $12,600 for a patient paying entirely out of pocket. That is a clinically relevant financial difference. At the same time, compounded preparations differ from FDA-approved products in ways patients deserve to know.

FDA-approved semaglutide (Wegovy) and tirzepatide (Zepbound) have passed the agency's full drug approval process, including manufacturing quality audits, stability testing, and bioavailability studies. Compounded preparations produced by 503A pharmacies are patient-specific and not subject to the same pre-approval review. 503B facilities face more oversight but still operate under a different regulatory structure than a brand manufacturer. The FDA has warned that some compounders have added ingredients such as vitamin B12, cyanocobalamin, or NAD+ without clinical evidence supporting benefit, and that dosing errors in compounded injectables have led to adverse events.

The HealthRX clinical team uses a four-question framework when patients ask about compounded GLP-1 cost:

1. Does the patient have a qualifying diagnosis (T2D, obesity with BMI <30, or obesity with comorbidity) that makes brand-name insurance coverage realistic?
2. Has prior authorization been attempted, and if denied, has the appeal process been used?
3. Is the LillyDirect vial program ($349 to $499/month) a viable self-pay option for tirzepatide?
4. If compounded is chosen, is the pharmacy a state-licensed 503A or 503B facility with verifiable accreditation?

Only after working through all four questions does the team move to recommending a compounded product as the primary path.

Savings Programs and Alternative Channels

Several manufacturer programs and alternative purchasing channels meaningfully reduce brand-name costs.

NovoCare (Novo Nordisk): Uninsured patients with income at or below 400% of the federal poverty level may receive Wegovy or Ozempic at no cost. Commercially insured patients with a savings card may pay as little as $25 to $99 per month. Program terms are subject to annual change and income verification.

LillyDirect (Eli Lilly): Zepbound single-dose vials are available directly from Eli Lilly via LillyDirect for $349 per month (2.5 mg and 5 mg doses) and $499 per month (10 mg and 15 mg doses) for self-pay patients without insurance coverage. This is a significant reduction from the $1,060 list price. Mounjaro is not currently available through the same direct-pay channel.

GoodRx and pharmacy discount cards: GoodRx pricing for Ozempic at common pharmacies ranges from $800 to $950 per month as of mid-2025, which offers marginal but real savings off list price for uninsured patients. Discount cards do not combine with insurance.

Canadian and international pharmacy programs: Some patients pursue lower-cost brand-name product through certified international pharmacies. This is legal for personal use under certain FDA enforcement policies but involves regulatory risk and supply chain uncertainty that must be weighed against cost savings.

The Clinical Case for Staying at Effective Doses

One cost consideration that does not appear in simple price comparisons is dose adequacy. Both STEP-1 and SURMOUNT-1 achieved their headline weight loss numbers at the highest approved doses: semaglutide 2.4 mg weekly and tirzepatide 15 mg weekly, respectively. The STEP-5 trial (N=304) demonstrated that the mean 15.2% weight loss at 52 weeks with semaglutide 2.4 mg was maintained at 104 weeks, suggesting durable benefit at full dose [10].

Choosing a lower-cost compounded product at a sub-therapeutic dose to save money each month, only to achieve minimal weight loss, is not actually cost-effective. Patients who start at 0.5 mg compounded semaglutide and never titrate above 1 mg are not receiving the dose that generated the 14.9% weight loss in STEP-1. The titration schedule matters, and monthly cost at the starting dose underestimates total cost at the therapeutic dose.

STEP-3 (N=611) showed that adding intensive behavioral therapy to semaglutide 2.4 mg produced 16% mean weight loss versus 13.7% with semaglutide alone at 68 weeks, and adding counseling did not materially change the medication cost [11]. The behavioral component is essentially free relative to the drug cost in most programs, and it adds measurable outcome benefit.

STEP-8 (N=338) compared semaglutide 2.4 mg directly against liraglutide 3.0 mg. Semaglutide produced 15.8% weight loss versus 6.4% with liraglutide at 68 weeks (P<0.001) [12]. Liraglutide 3.0 mg (brand name Saxenda) lists at roughly $1,400 per month and requires daily injection, making it both less effective and no cheaper than Wegovy for most patients. This comparison contextualizes why providers moved away from liraglutide when semaglutide became available.

What HealthRX Physicians Typically Recommend

The path a HealthRX physician recommends depends on the patient's insurance status, comorbidities, and tolerance for the regulatory considerations associated with compounded products.

For a commercially insured patient with T2D, the starting point is a prior authorization attempt for Ozempic or Mounjaro, where coverage is most reliable. For a commercially insured patient with obesity without T2D, the physician initiates a prior authorization for Wegovy or Zepbound, documents the BMI and comorbidity, and prepares for a possible first-level denial. If the LillyDirect vial program is viable ($349 to $499 per month), it represents a compelling self-pay option for tirzepatide without the regulatory concerns of compounding.

For an uninsured patient who cannot access manufacturer assistance programs and for whom the brand-name self-pay options remain financially out of reach, a compounded product from a verified 503A or 503B pharmacy at the full therapeutic titration schedule is a reasonable clinical choice, with the understanding that FDA-approved product would be preferred if cost were not a barrier.

HealthRX physicians do not recommend compounded GLP-1 preparations from pharmacies that cannot provide a state license number, a PCAB accreditation, or a 503B FDA registration. Those verification steps take under five minutes and eliminate the highest-risk sources.

SURMOUNT-3 (N=579) is relevant to this conversation: it showed that patients who completed a 12-week intensive lifestyle intervention before starting tirzepatide lost 26.2% of body weight by week 72, compared with 18.8% for patients who started tirzepatide directly [13]. The 7.4 percentage point advantage for the lifestyle-first group came at essentially zero drug cost during those 12 weeks. For patients with time and motivation, that pre-drug lifestyle period may shift the financial calculation.

Frequently Asked Questions